Alivexis

Executive Summary

Alivexis is a Japan-based, technology-driven drug discovery company focused on developing small-molecule targeted therapeutics for oncology, immune-inflammatory diseases, and rare diseases. Founded in 2020 and headquartered in Tokyo, the company leverages its proprietary ModBind™ simulation engine and advanced structural analysis platform to address difficult biological targets. Its preclinical pipeline includes clinical candidates targeting Cathepsin C, KIT, PARG, and WDR5. The company operates in the preclinical stage as a private entity with an estimated valuation, though total raised and specific valuation are not publicly disclosed. With a small team of 10-50 employees, Alivexis aims to differentiate itself through computational drug design, potentially enabling faster and more efficient discovery of novel therapies for indications with high unmet need. Given its early-stage status and limited public information, the company's near-term prospects are uncertain. The ModBind platform, while promising, has yet to yield clinical data, and the competitive landscape in small-molecule oncology and immunology is intense. However, Alivexis's focus on multiple targets—including Cathepsin C (autoimmune), KIT (gastrointestinal stromal tumors), PARG (synthetic lethality in cancer), and WDR5 (cancer epigenetics)—provides diversification. The company's success will depend on advancing programs to IND and securing partnerships or funding. Currently, no major upcoming catalysts are publicly identifiable, but progression of any candidate into clinical development would be a significant milestone.